Model Seraccess -Disruptive Technology for Monitoring Critical Blood Parameters
In its MedTech division, Securecell is proudly developing Seraccess®, an innovative technology that fully automates the high-frequency collection, processing, and analysis of blood using next generation microfluidics for the monitoring and controlling of critical blood parameters using the smallest blood sample possible. Seraccess® innovation begins with an ultra precise / fully automated Glucose ICU monitor and ends with a fully miniaturized / fully mobile artificial pancreas device for personalized life-changing glucose control.
The automated, regular, accurate and precise glucose measurement provided by Seraccess® will empower confident treatment decisions and lead to improved clinical outcomes. Furthermore, hospitals will benefit from significant cost reduction by eliminating manual glucose measurements.